Catalyst Pharmaceutical
CPRX
CPRX was delisted on the 14th of July, 2026.
117 hedge funds and large institutions have $327M invested in Catalyst Pharmaceutical in 2019 Q3 according to their latest regulatory filings, with 29 funds opening new positions, 41 increasing their positions, 28 reducing their positions, and 13 closing their positions.
123% more first-time investments, than exits
New positions opened: 29 | Existing positions closed: 13
100% more funds holding in top 10
Funds holding in top 10: 1 → 2 (+1)
46% more repeat investments, than reductions
Existing positions increased: 41 | Existing positions reduced: 28
38% more capital invested
Capital invested by funds: $236M → $327M (+$90.9M)
16% more funds holding
Funds holding: 101 → 117 (+16)
0.03% less ownership
Funds ownership: 59.85% → 59.82% (-0.03%)
65% less call options, than puts
Call options by funds: $377K | Put options by funds: $1.08M
Top Buyers
| 1 |
State Street
Boston,
Massachusetts
|
+$9.62M |
| 2 |
EA
Emerald Advisers
Leola,
Pennsylvania
|
+$6.26M |
| 3 |
EMFAT
Emerald Mutual Fund Advisers Trust
Leola,
Pennsylvania
|
+$5.77M |
| 4 |
Goldman Sachs
New York
|
+$4.83M |
| 5 |
Prudential Financial
Newark,
New Jersey
|
+$3.31M |
Top Sellers
| 1 |
AC
Armistice Capital
New York
|
-$19.2M |
| 2 |
BC
Broadfin Capital
New York
|
-$10M |
| 3 |
MP
Mangrove Partners
Greenwich,
Connecticut
|
-$7.08M |
| 4 |
BBA
Baker Bros. Advisors
New York
|
-$6.49M |
| 5 |
DMK
David M. Knott
|
-$1.02M |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
126
Connor, Clark & Lunn Investment Management (CC&L)
Vancouver,
British Columbia, Canada
| – | -$55K | -14,332 | Closed |
|
|
TSS
127
Two Sigma Securities
New York
| – | -$40K | -10,336 | Closed |
|
128
Canada Life
Winnipeg,
Manitoba, Canada
| – | -$39K | -10,227 | Closed |
|
|
AA
129
AlphaMark Advisors
Ft. Wright,
Kentucky
| – | -$8K | -2,208 | Closed |
|
|
AG
130
Aperio Group
Sausalito,
California
| – | -$1K | -192 | Closed |
|
CPRX Hedge Fund Activity: Q3 2019 in Review
117 of the 4,560 institutional investors tracked by Wall St. Rank reported a position in Catalyst Pharmaceutical (CPRX) for Q3 2019, worth a combined $327M — up 38% from $236M a quarter earlier.
Buyers outnumbered sellers: 29 funds opened new CPRX positions and 13 closed out — a net gain of 16 holders — while 41 added to existing stakes and 28 trimmed.
The largest buyer was State Street, adding an estimated $9.62M. The largest seller was Armistice Capital, exiting entirely with an estimated $19.2M sold.
- 117 institutional investors held Catalyst Pharmaceutical (CPRX) as of Q3 2019, up from 101 in Q2 2019.
- Funds reported $327M of Catalyst Pharmaceutical stock for Q3 2019, up 38% quarter-over-quarter.
- 29 funds opened new Catalyst Pharmaceutical positions in Q3 2019 and 13 closed out, a net change of +16 holders.
- The largest Catalyst Pharmaceutical buyer in Q3 2019 was State Street, an estimated $9.62M added.
- The largest Catalyst Pharmaceutical seller in Q3 2019 was Armistice Capital, an estimated $19.2M sold.
Based on aggregated 13F filings for Q3 2019.